norcantharidin has been researched along with Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Huang, W; Huang, X; Li, H; Wang, J; Yan, D | 1 |
| Cao, T; Deng, T; Fu, Y; Gao, Y; Hou, Y; Li, X; Liu, Y; Peng, Y; Qi, X; Xie, L; Yin, L; Zhang, S; Zhu, Q | 1 |
| Cheng, JX; Fan, Y; Guo, DY; Shi, YJ; Sun, J; Tian, H; Zhai, BT; Zhang, XF; Zou, JB | 1 |
| Herrmann, P; Ishfaq, MA; Schöpe, PC; Shoemaker, RH; Smith, J; Stein, U; Walther, W; Zinnow, V | 1 |
| Cao, Z; Guo, C; Li, Y; Ren, Y; Song, X; Tan, L; Wang, M; Zhou, J | 1 |
| Guo, A; Guo, S; Jiang, J; Li, M; Li, Y; Liu, J; Lv, L; Shen, Y; Wang, F; Xu, X | 1 |
| Kouznetsov, VV; Puerto Galvis, CE; Vargas Méndez, LY | 1 |
| Chen, SW; Guan, XW; Hui, L; Zhao, J | 1 |
| Campbell, BE; Gasser, RB; Gilbert, J; Gordon, CP; McCluskey, A; Sakoff, JA; Tarleton, M | 1 |
| Deng, L; Tang, S | 1 |
| Ackland, SP; Gilbert, J; Hill, TA; McCluskey, A; Sakoff, JA; Sauer, B; Stewart, SG | 1 |
5 review(s) available for norcantharidin and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Review targeted drug delivery systems for norcantharidin in cancer therapy.
Topics: Biological Availability; Bridged Bicyclo Compounds, Heterocyclic; Drug Delivery Systems; Half-Life; Neoplasms; United States | 2022 |
Norcantharidin: research advances in pharmaceutical activities and derivatives in recent years.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; Cell Proliferation; Humans; Medicine, Chinese Traditional; Neoplasms | 2020 |
Cantharidin-based small molecules as potential therapeutic agents.
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; Cell Survival; Coleoptera; Enzyme Activation; Humans; Neoplasms; Phosphoprotein Phosphatases | 2013 |
Norcantharidin analogues: a patent review (2006 - 2010).
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Design; Humans; Leukocytes; Neoplasms; Patents as Topic; Phosphoprotein Phosphatases | 2011 |
7 other study(ies) available for norcantharidin and Neoplasms
| Article | Year |
|---|---|
Two Zn(II) coordination polymers with anticancer drug norcantharidin as ligands for cancer chemotherapy.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Delivery Systems; Ligands; Nanoparticles; Neoplasms; Polymers; Zinc | 2022 |
Norcantharidin promotes cancer radiosensitization through Cullin1 neddylation-mediated CDC6 protein degradation.
Topics: Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Proteins; Cullin Proteins; Humans; Neoplasms; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteolysis; RNA, Small Interfering; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ubiquitins | 2022 |
Cantharidin and Its Analogue Norcantharidin Inhibit Metastasis-Inducing Genes S100A4 and MACC1.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; Colorectal Neoplasms; Humans; Neoplasms; S100 Calcium-Binding Protein A4; Trans-Activators; Transcription Factors | 2023 |
Synthesis, in vitro and in vivo evaluation of new norcantharidin-conjugated hydroxypropyltrimethyl ammonium chloride chitosan derivatives as polymer therapeutics.
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Chitosan; Endocytosis; Humans; Male; Mice; Neoplasms; Polymers; Quaternary Ammonium Compounds | 2013 |
Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Cells, Cultured; DNA; Enzyme Inhibitors; Fibroblasts; Heterocyclic Compounds, 2-Ring; Humans; Inhibitory Concentration 50; Microtubules; Molecular Structure; Neoplasms; Protein Phosphatase 1; Structure-Activity Relationship; Sulfonamides | 2015 |
Norcantharidin analogues with nematocidal activity in Haemonchus contortus.
Topics: Animals; Antinematodal Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cell Line, Tumor; Drug Design; Haemonchus; Humans; Molecular Structure; Neoplasms | 2011 |
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2007 |